| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 83 | 2024 | 398 | 10.780 |
Why?
|
| Radiation Oncology | 28 | 2022 | 83 | 6.240 |
Why?
|
| Lung Neoplasms | 62 | 2025 | 2674 | 3.770 |
Why?
|
| Prostatic Neoplasms | 29 | 2020 | 972 | 3.170 |
Why?
|
| Brain Neoplasms | 36 | 2025 | 1324 | 2.930 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 31 | 2025 | 1194 | 2.610 |
Why?
|
| Radiotherapy | 17 | 2016 | 209 | 2.360 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 33 | 2025 | 150 | 2.200 |
Why?
|
| Liver Neoplasms | 21 | 2019 | 774 | 1.960 |
Why?
|
| Neoplasms | 29 | 2025 | 2944 | 1.890 |
Why?
|
| Radiotherapy Dosage | 46 | 2023 | 289 | 1.830 |
Why?
|
| Radiotherapy, Conformal | 18 | 2017 | 75 | 1.820 |
Why?
|
| Radiotherapy, Intensity-Modulated | 16 | 2019 | 143 | 1.690 |
Why?
|
| Radiation Injuries | 16 | 2018 | 149 | 1.690 |
Why?
|
| Glioblastoma | 13 | 2025 | 349 | 1.620 |
Why?
|
| Four-Dimensional Computed Tomography | 9 | 2025 | 38 | 1.610 |
Why?
|
| Cone-Beam Computed Tomography | 10 | 2025 | 32 | 1.470 |
Why?
|
| Small Cell Lung Carcinoma | 6 | 2023 | 125 | 1.410 |
Why?
|
| Cranial Irradiation | 7 | 2020 | 85 | 1.320 |
Why?
|
| Brachytherapy | 16 | 2016 | 132 | 1.270 |
Why?
|
| Chemoradiotherapy | 10 | 2025 | 238 | 1.250 |
Why?
|
| Dacarbazine | 9 | 2016 | 98 | 1.160 |
Why?
|
| Pulmonary Ventilation | 5 | 2021 | 80 | 1.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 7 | 2025 | 76 | 1.060 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2026 | 222 | 1.020 |
Why?
|
| Humans | 230 | 2026 | 145625 | 1.010 |
Why?
|
| Aged | 104 | 2026 | 26251 | 0.980 |
Why?
|
| Societies, Medical | 9 | 2021 | 901 | 0.940 |
Why?
|
| Aged, 80 and over | 56 | 2025 | 8351 | 0.840 |
Why?
|
| Middle Aged | 107 | 2026 | 36359 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2026 | 1156 | 0.830 |
Why?
|
| Uterine Cervical Neoplasms | 10 | 2016 | 269 | 0.820 |
Why?
|
| SEER Program | 10 | 2018 | 233 | 0.800 |
Why?
|
| Astrocytoma | 5 | 2025 | 128 | 0.750 |
Why?
|
| Radiation Oncologists | 2 | 2022 | 3 | 0.750 |
Why?
|
| Neoplasm Metastasis | 10 | 2020 | 693 | 0.740 |
Why?
|
| Radiation Pneumonitis | 6 | 2021 | 31 | 0.720 |
Why?
|
| Radiometry | 10 | 2022 | 56 | 0.710 |
Why?
|
| Male | 118 | 2026 | 73014 | 0.710 |
Why?
|
| Dose-Response Relationship, Radiation | 20 | 2021 | 141 | 0.690 |
Why?
|
| Neoplasm Staging | 24 | 2018 | 1486 | 0.680 |
Why?
|
| Whole-Body Irradiation | 4 | 2020 | 73 | 0.670 |
Why?
|
| Social Media | 2 | 2020 | 158 | 0.660 |
Why?
|
| Neoplasm Grading | 6 | 2016 | 313 | 0.660 |
Why?
|
| Databases, Factual | 10 | 2017 | 1481 | 0.650 |
Why?
|
| Scattering, Radiation | 6 | 2025 | 98 | 0.650 |
Why?
|
| Internship and Residency | 5 | 2022 | 1269 | 0.630 |
Why?
|
| Medicine | 2 | 2021 | 126 | 0.620 |
Why?
|
| Videoconferencing | 1 | 2020 | 62 | 0.620 |
Why?
|
| Registries | 5 | 2018 | 2382 | 0.620 |
Why?
|
| Liver | 9 | 2018 | 1859 | 0.610 |
Why?
|
| Travel | 1 | 2020 | 133 | 0.590 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2007 | 627 | 0.590 |
Why?
|
| ErbB Receptors | 12 | 2025 | 636 | 0.590 |
Why?
|
| Radiation | 1 | 2019 | 24 | 0.590 |
Why?
|
| United States | 31 | 2022 | 16041 | 0.580 |
Why?
|
| Models, Economic | 1 | 2019 | 63 | 0.570 |
Why?
|
| Combined Modality Therapy | 25 | 2019 | 1269 | 0.570 |
Why?
|
| Respiratory Function Tests | 3 | 2023 | 543 | 0.570 |
Why?
|
| Female | 107 | 2026 | 79080 | 0.560 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2009 | 158 | 0.560 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 97 | 0.550 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2015 | 229 | 0.550 |
Why?
|
| Kidney Neoplasms | 6 | 2015 | 417 | 0.540 |
Why?
|
| Quality of Life | 8 | 2025 | 3187 | 0.530 |
Why?
|
| Treatment Outcome | 33 | 2025 | 11744 | 0.520 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 200 | 0.520 |
Why?
|
| Adult | 73 | 2026 | 40821 | 0.520 |
Why?
|
| Stereotaxic Techniques | 3 | 2006 | 42 | 0.510 |
Why?
|
| Lung | 11 | 2024 | 4119 | 0.510 |
Why?
|
| Prospective Studies | 27 | 2026 | 8087 | 0.510 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2024 | 982 | 0.510 |
Why?
|
| Breast Neoplasms | 11 | 2022 | 2411 | 0.510 |
Why?
|
| Faculty, Medical | 1 | 2020 | 305 | 0.500 |
Why?
|
| Prostate-Specific Antigen | 8 | 2016 | 162 | 0.500 |
Why?
|
| Neoplasms, Second Primary | 2 | 2008 | 103 | 0.490 |
Why?
|
| Antineoplastic Agents | 13 | 2023 | 2218 | 0.470 |
Why?
|
| Preoperative Care | 2 | 2018 | 375 | 0.470 |
Why?
|
| Radiotherapy, Computer-Assisted | 6 | 2015 | 12 | 0.470 |
Why?
|
| Insurance Coverage | 4 | 2019 | 246 | 0.450 |
Why?
|
| Organs at Risk | 5 | 2021 | 37 | 0.450 |
Why?
|
| Models, Biological | 8 | 2018 | 1758 | 0.440 |
Why?
|
| Androgen Antagonists | 6 | 2020 | 91 | 0.440 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 15 | 0.430 |
Why?
|
| Radiation Tolerance | 7 | 2015 | 101 | 0.430 |
Why?
|
| Disease-Free Survival | 12 | 2019 | 777 | 0.420 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 133 | 0.410 |
Why?
|
| Health Physics | 2 | 2016 | 7 | 0.410 |
Why?
|
| Immunologic Factors | 1 | 2016 | 244 | 0.410 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 66 | 0.400 |
Why?
|
| Checklist | 1 | 2015 | 105 | 0.400 |
Why?
|
| Beauty | 1 | 2013 | 19 | 0.400 |
Why?
|
| Spiral Cone-Beam Computed Tomography | 2 | 2023 | 5 | 0.390 |
Why?
|
| Clinical Trials as Topic | 9 | 2017 | 1062 | 0.390 |
Why?
|
| Artifacts | 4 | 2019 | 142 | 0.380 |
Why?
|
| Phantoms, Imaging | 5 | 2023 | 159 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2023 | 3917 | 0.380 |
Why?
|
| Liver Regeneration | 2 | 2012 | 41 | 0.370 |
Why?
|
| Credentialing | 1 | 2012 | 21 | 0.370 |
Why?
|
| Proton Therapy | 2 | 2015 | 16 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2019 | 959 | 0.360 |
Why?
|
| Follow-Up Studies | 19 | 2026 | 5397 | 0.360 |
Why?
|
| Medicare | 4 | 2021 | 907 | 0.360 |
Why?
|
| Oxygen | 5 | 2016 | 996 | 0.350 |
Why?
|
| Retrospective Studies | 35 | 2024 | 17291 | 0.350 |
Why?
|
| Survival Analysis | 11 | 2020 | 1372 | 0.350 |
Why?
|
| Hemoglobin A | 2 | 2002 | 21 | 0.350 |
Why?
|
| Antibodies | 2 | 2018 | 395 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2019 | 1996 | 0.340 |
Why?
|
| Rectum | 4 | 2014 | 180 | 0.340 |
Why?
|
| Carcinoma | 2 | 2006 | 225 | 0.330 |
Why?
|
| Lymph Nodes | 1 | 2014 | 511 | 0.330 |
Why?
|
| Relative Biological Effectiveness | 2 | 2008 | 4 | 0.330 |
Why?
|
| Prognosis | 16 | 2026 | 4331 | 0.320 |
Why?
|
| Survival Rate | 13 | 2019 | 2078 | 0.320 |
Why?
|
| Erlotinib Hydrochloride | 4 | 2019 | 71 | 0.320 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2008 | 17 | 0.320 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 805 | 0.310 |
Why?
|
| Comparative Effectiveness Research | 1 | 2011 | 170 | 0.310 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 502 | 0.310 |
Why?
|
| Antigens, Neoplasm | 3 | 2009 | 271 | 0.300 |
Why?
|
| Stomach | 1 | 2010 | 106 | 0.300 |
Why?
|
| Meningeal Neoplasms | 3 | 2026 | 95 | 0.300 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 402 | 0.290 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2002 | 43 | 0.290 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 1318 | 0.290 |
Why?
|
| Positron-Emission Tomography | 6 | 2019 | 342 | 0.290 |
Why?
|
| Career Choice | 2 | 2021 | 235 | 0.290 |
Why?
|
| Cell Hypoxia | 3 | 2002 | 247 | 0.280 |
Why?
|
| Intestine, Small | 1 | 2010 | 160 | 0.280 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2015 | 226 | 0.280 |
Why?
|
| Antigens, CD | 2 | 2009 | 559 | 0.270 |
Why?
|
| Respiratory Mechanics | 1 | 2008 | 74 | 0.270 |
Why?
|
| Quinazolines | 6 | 2014 | 267 | 0.270 |
Why?
|
| Risk Assessment | 4 | 2015 | 3678 | 0.260 |
Why?
|
| Vision, Ocular | 1 | 2008 | 47 | 0.260 |
Why?
|
| Radiation Protection | 2 | 2009 | 41 | 0.260 |
Why?
|
| Head and Neck Neoplasms | 3 | 2008 | 563 | 0.260 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 70 | 0.260 |
Why?
|
| Meningioma | 2 | 2026 | 87 | 0.260 |
Why?
|
| Orbit | 1 | 2008 | 67 | 0.250 |
Why?
|
| Prostatectomy | 3 | 2014 | 93 | 0.250 |
Why?
|
| Medical Oncology | 3 | 2020 | 344 | 0.250 |
Why?
|
| Spinal Neoplasms | 2 | 2007 | 36 | 0.250 |
Why?
|
| Linear Models | 2 | 2010 | 847 | 0.250 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2007 | 27 | 0.250 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2006 | 34 | 0.240 |
Why?
|
| Pyrazoles | 4 | 2021 | 516 | 0.240 |
Why?
|
| Bone Neoplasms | 4 | 2019 | 271 | 0.240 |
Why?
|
| Urologic Diseases | 1 | 2006 | 42 | 0.240 |
Why?
|
| Anesthetics, Intravenous | 1 | 2006 | 67 | 0.240 |
Why?
|
| Aniline Compounds | 3 | 2024 | 120 | 0.240 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2006 | 2 | 0.240 |
Why?
|
| Cancer Vaccines | 1 | 2007 | 161 | 0.230 |
Why?
|
| Pyridines | 4 | 2021 | 606 | 0.230 |
Why?
|
| Melanoma | 3 | 2018 | 764 | 0.230 |
Why?
|
| Patient Selection | 3 | 2021 | 720 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 207 | 0.230 |
Why?
|
| Algorithms | 7 | 2017 | 1843 | 0.230 |
Why?
|
| Propofol | 1 | 2006 | 86 | 0.230 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2025 | 40 | 0.230 |
Why?
|
| Colorectal Neoplasms | 4 | 2017 | 870 | 0.230 |
Why?
|
| Tumor Burden | 9 | 2014 | 326 | 0.230 |
Why?
|
| Time Factors | 9 | 2021 | 7079 | 0.230 |
Why?
|
| Necrosis | 4 | 2022 | 243 | 0.220 |
Why?
|
| Lymphocyte Activation | 2 | 2009 | 1136 | 0.220 |
Why?
|
| Data Mining | 2 | 2016 | 113 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 387 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 379 | 0.220 |
Why?
|
| Central Nervous System | 3 | 2023 | 278 | 0.220 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 411 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 257 | 0.210 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2019 | 71 | 0.210 |
Why?
|
| CTLA-4 Antigen | 3 | 2018 | 105 | 0.210 |
Why?
|
| Particle Accelerators | 3 | 2019 | 9 | 0.210 |
Why?
|
| Insurance, Health | 2 | 2018 | 315 | 0.210 |
Why?
|
| Dendritic Cells | 1 | 2007 | 507 | 0.200 |
Why?
|
| Propionates | 2 | 2001 | 39 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2015 | 2766 | 0.200 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2007 | 356 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2015 | 429 | 0.200 |
Why?
|
| Rectal Neoplasms | 4 | 2008 | 159 | 0.190 |
Why?
|
| Virtual Reality | 1 | 2025 | 82 | 0.190 |
Why?
|
| Comprehension | 1 | 2025 | 175 | 0.190 |
Why?
|
| Oncogene Addiction | 1 | 2023 | 6 | 0.190 |
Why?
|
| Pyrimidines | 3 | 2024 | 530 | 0.190 |
Why?
|
| Carbon Dioxide | 2 | 2002 | 228 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 369 | 0.190 |
Why?
|
| Inappropriate ADH Syndrome | 2 | 1993 | 7 | 0.190 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 1993 | 21 | 0.190 |
Why?
|
| Radiopharmaceuticals | 3 | 2014 | 210 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 446 | 0.190 |
Why?
|
| Radiography | 6 | 2014 | 856 | 0.180 |
Why?
|
| Patient Education as Topic | 3 | 2025 | 769 | 0.180 |
Why?
|
| Analysis of Variance | 4 | 2016 | 1293 | 0.170 |
Why?
|
| Propensity Score | 4 | 2018 | 370 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 165 | 0.170 |
Why?
|
| Consensus | 2 | 2022 | 465 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 429 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 1581 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 1148 | 0.170 |
Why?
|
| Pandemics | 2 | 2020 | 1700 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2021 | 41 | 0.170 |
Why?
|
| Pelvis | 3 | 2023 | 129 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2025 | 578 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 55 | 0.160 |
Why?
|
| Gene Rearrangement | 3 | 2018 | 155 | 0.160 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 335 | 0.160 |
Why?
|
| Erythropoietin | 1 | 2001 | 100 | 0.160 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 727 | 0.160 |
Why?
|
| Palatal Neoplasms | 1 | 2000 | 6 | 0.160 |
Why?
|
| Technology, Radiologic | 2 | 2010 | 6 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2023 | 615 | 0.150 |
Why?
|
| Radiographic Image Enhancement | 1 | 2000 | 56 | 0.150 |
Why?
|
| Anemia | 1 | 2001 | 189 | 0.150 |
Why?
|
| Electromagnetic Phenomena | 1 | 2019 | 24 | 0.150 |
Why?
|
| Brain | 4 | 2022 | 2981 | 0.150 |
Why?
|
| Suggestion | 1 | 2019 | 2 | 0.150 |
Why?
|
| Pelvic Neoplasms | 1 | 1999 | 24 | 0.150 |
Why?
|
| Relative Value Scales | 1 | 2019 | 5 | 0.150 |
Why?
|
| Fluoroscopy | 1 | 2000 | 177 | 0.150 |
Why?
|
| Thoracic Neoplasms | 3 | 2015 | 40 | 0.150 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 11 | 0.150 |
Why?
|
| Mass Screening | 1 | 2008 | 1300 | 0.150 |
Why?
|
| Clinical Coding | 1 | 2019 | 28 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2001 | 225 | 0.150 |
Why?
|
| Adenocarcinoma | 4 | 2008 | 927 | 0.140 |
Why?
|
| Epidermal Growth Factor | 2 | 1998 | 157 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2026 | 1334 | 0.140 |
Why?
|
| Cell Survival | 5 | 2008 | 1102 | 0.140 |
Why?
|
| Piperidines | 3 | 2024 | 223 | 0.140 |
Why?
|
| Radiography, Interventional | 1 | 2000 | 127 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 122 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2000 | 170 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2000 | 100 | 0.140 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1998 | 165 | 0.140 |
Why?
|
| Radiobiology | 4 | 2008 | 7 | 0.140 |
Why?
|
| Farms | 1 | 2018 | 8 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 774 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2018 | 6045 | 0.140 |
Why?
|
| Glioma | 3 | 2010 | 425 | 0.140 |
Why?
|
| Aquaporin 4 | 1 | 2019 | 101 | 0.140 |
Why?
|
| Policy | 1 | 2019 | 147 | 0.140 |
Why?
|
| Industry | 1 | 2018 | 43 | 0.130 |
Why?
|
| Karnofsky Performance Status | 3 | 2015 | 37 | 0.130 |
Why?
|
| Intensive Care Units | 2 | 2007 | 923 | 0.130 |
Why?
|
| Organ Size | 3 | 2018 | 463 | 0.130 |
Why?
|
| Cell Division | 2 | 1997 | 735 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1531 | 0.130 |
Why?
|
| Frontal Lobe | 1 | 1998 | 159 | 0.130 |
Why?
|
| Health Priorities | 1 | 2017 | 45 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 121 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 1403 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 277 | 0.130 |
Why?
|
| Health Planning | 1 | 2017 | 46 | 0.130 |
Why?
|
| Urinary Bladder | 2 | 2010 | 194 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 4 | 2010 | 216 | 0.130 |
Why?
|
| Respiration, Artificial | 1 | 2002 | 711 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 30 | 0.120 |
Why?
|
| Thymoma | 1 | 2017 | 38 | 0.120 |
Why?
|
| Vascular Resistance | 1 | 2018 | 365 | 0.120 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2016 | 2 | 0.120 |
Why?
|
| Postoperative Care | 2 | 2017 | 292 | 0.120 |
Why?
|
| Risk Factors | 7 | 2016 | 10840 | 0.120 |
Why?
|
| Cause of Death | 2 | 2017 | 455 | 0.120 |
Why?
|
| Flunarizine | 2 | 1993 | 2 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2017 | 150 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 268 | 0.120 |
Why?
|
| Monitoring, Intraoperative | 1 | 2016 | 65 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 6050 | 0.120 |
Why?
|
| Pulmonary Atelectasis | 1 | 2015 | 15 | 0.120 |
Why?
|
| Disease Progression | 7 | 2019 | 2857 | 0.110 |
Why?
|
| Health Expenditures | 1 | 2017 | 196 | 0.110 |
Why?
|
| Ventricular Function, Right | 1 | 2018 | 300 | 0.110 |
Why?
|
| Perioperative Care | 1 | 2018 | 229 | 0.110 |
Why?
|
| Neurosurgery | 1 | 2015 | 39 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 203 | 0.110 |
Why?
|
| Oximetry | 1 | 2016 | 124 | 0.110 |
Why?
|
| Salvage Therapy | 4 | 2017 | 163 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 782 | 0.110 |
Why?
|
| Health Services Research | 1 | 2017 | 389 | 0.110 |
Why?
|
| Stroke Volume | 1 | 2018 | 651 | 0.110 |
Why?
|
| Precision Medicine | 2 | 2017 | 462 | 0.110 |
Why?
|
| Vaginal Neoplasms | 1 | 1994 | 20 | 0.110 |
Why?
|
| Perineum | 1 | 1994 | 36 | 0.110 |
Why?
|
| Induction Chemotherapy | 2 | 2013 | 87 | 0.110 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 541 | 0.110 |
Why?
|
| Marital Status | 1 | 2014 | 47 | 0.110 |
Why?
|
| Quality Control | 5 | 2013 | 162 | 0.100 |
Why?
|
| Maytansine | 1 | 2014 | 18 | 0.100 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2014 | 7 | 0.100 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2014 | 11 | 0.100 |
Why?
|
| Multimodal Imaging | 2 | 2013 | 138 | 0.100 |
Why?
|
| Nuclear Medicine | 1 | 2014 | 9 | 0.100 |
Why?
|
| Prostate | 1 | 2015 | 159 | 0.100 |
Why?
|
| Risk | 3 | 2016 | 917 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 1992 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 133 | 0.100 |
Why?
|
| Brain Edema | 1 | 2014 | 63 | 0.100 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2013 | 3 | 0.100 |
Why?
|
| Takayasu Arteritis | 1 | 1994 | 16 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 567 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 23 | 0.100 |
Why?
|
| Incidence | 3 | 2016 | 2910 | 0.100 |
Why?
|
| Xerostomia | 1 | 1993 | 13 | 0.100 |
Why?
|
| Clinical Competence | 2 | 2022 | 1261 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 1994 | 56 | 0.100 |
Why?
|
| Blood Viscosity | 1 | 1993 | 19 | 0.100 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 293 | 0.100 |
Why?
|
| Health Care Reform | 1 | 2014 | 109 | 0.100 |
Why?
|
| Observer Variation | 1 | 2014 | 355 | 0.100 |
Why?
|
| Lactates | 1 | 1993 | 82 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2018 | 762 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1429 | 0.090 |
Why?
|
| Calcium | 2 | 1998 | 1181 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2016 | 321 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2025 | 1878 | 0.090 |
Why?
|
| Erythrocytes | 2 | 2001 | 749 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 1754 | 0.090 |
Why?
|
| Motion | 2 | 2011 | 94 | 0.090 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 364 | 0.090 |
Why?
|
| Young Adult | 10 | 2025 | 14240 | 0.090 |
Why?
|
| Partial Pressure | 2 | 2002 | 30 | 0.090 |
Why?
|
| Age Factors | 2 | 2021 | 3321 | 0.090 |
Why?
|
| Organ Specificity | 2 | 2021 | 306 | 0.090 |
Why?
|
| Physicians | 1 | 2020 | 954 | 0.090 |
Why?
|
| Hepatic Veins | 1 | 2011 | 28 | 0.090 |
Why?
|
| Radiology | 1 | 2014 | 175 | 0.090 |
Why?
|
| Oxytocin | 1 | 1992 | 51 | 0.090 |
Why?
|
| Eponyms | 1 | 1991 | 2 | 0.080 |
Why?
|
| Remission Induction | 3 | 2008 | 308 | 0.080 |
Why?
|
| Colorado | 5 | 2015 | 4588 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 728 | 0.080 |
Why?
|
| Radiation Dosage | 4 | 2019 | 193 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2017 | 724 | 0.080 |
Why?
|
| Protons | 1 | 2011 | 96 | 0.080 |
Why?
|
| Keratin-18 | 1 | 2010 | 12 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 501 | 0.080 |
Why?
|
| Esophagectomy | 1 | 1992 | 136 | 0.080 |
Why?
|
| Burkitt Lymphoma | 1 | 1991 | 61 | 0.080 |
Why?
|
| Carbazoles | 2 | 2024 | 53 | 0.080 |
Why?
|
| Computer Simulation | 3 | 2012 | 1014 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2026 | 721 | 0.080 |
Why?
|
| Esophageal Neoplasms | 2 | 2008 | 351 | 0.080 |
Why?
|
| Automation | 2 | 2020 | 104 | 0.080 |
Why?
|
| Respiration | 2 | 2023 | 207 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 143 | 0.080 |
Why?
|
| Mutation | 4 | 2025 | 4082 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 608 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 195 | 0.080 |
Why?
|
| Risk Management | 2 | 2020 | 80 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2022 | 347 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 57 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2010 | 240 | 0.070 |
Why?
|
| Immobilization | 2 | 2010 | 54 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2006 | 330 | 0.070 |
Why?
|
| Anthracyclines | 1 | 2009 | 49 | 0.070 |
Why?
|
| Thoracic Wall | 1 | 2009 | 22 | 0.070 |
Why?
|
| Rib Fractures | 1 | 2009 | 34 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2012 | 355 | 0.070 |
Why?
|
| Chest Pain | 1 | 2009 | 100 | 0.070 |
Why?
|
| Sex Factors | 1 | 2014 | 2101 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2010 | 177 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 140 | 0.070 |
Why?
|
| Cross-Priming | 1 | 2008 | 17 | 0.070 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2007 | 4 | 0.070 |
Why?
|
| DNA Repair | 2 | 2008 | 254 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 166 | 0.070 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2008 | 40 | 0.070 |
Why?
|
| Bile Duct Diseases | 1 | 2008 | 12 | 0.070 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2008 | 16 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2014 | 358 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 992 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 119 | 0.070 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2008 | 29 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 423 | 0.070 |
Why?
|
| Malaria Vaccines | 1 | 2007 | 11 | 0.070 |
Why?
|
| Hemocyanins | 1 | 2007 | 61 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 36 | 0.070 |
Why?
|
| Photons | 1 | 2008 | 67 | 0.070 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 62 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 926 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2009 | 929 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2016 | 1125 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2008 | 231 | 0.060 |
Why?
|
| Mouth Neoplasms | 1 | 2007 | 90 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 180 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2008 | 219 | 0.060 |
Why?
|
| Accreditation | 2 | 2022 | 100 | 0.060 |
Why?
|
| Adolescent | 7 | 2025 | 22451 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 339 | 0.060 |
Why?
|
| Software | 1 | 2012 | 673 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2010 | 3538 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2007 | 209 | 0.060 |
Why?
|
| Urinary Tract | 1 | 2006 | 47 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2007 | 2910 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 330 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 944 | 0.060 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2006 | 23 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2008 | 264 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 243 | 0.060 |
Why?
|
| Intestines | 1 | 2009 | 351 | 0.060 |
Why?
|
| Whole Body Imaging | 1 | 2006 | 29 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2009 | 341 | 0.060 |
Why?
|
| Cranial Nerve Diseases | 1 | 2006 | 42 | 0.060 |
Why?
|
| Physics | 4 | 2010 | 17 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 173 | 0.060 |
Why?
|
| Vertigo | 1 | 2006 | 40 | 0.060 |
Why?
|
| Heart | 2 | 2020 | 624 | 0.060 |
Why?
|
| Delirium | 1 | 2007 | 106 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2006 | 224 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 3396 | 0.060 |
Why?
|
| X-linked Nuclear Protein | 1 | 2025 | 9 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2026 | 189 | 0.060 |
Why?
|
| Cisplatin | 2 | 2011 | 346 | 0.060 |
Why?
|
| DNA Damage | 1 | 2008 | 437 | 0.060 |
Why?
|
| DNA Modification Methylases | 1 | 2025 | 19 | 0.060 |
Why?
|
| DNA Repair Enzymes | 1 | 2025 | 29 | 0.050 |
Why?
|
| Light | 1 | 2008 | 400 | 0.050 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2025 | 71 | 0.050 |
Why?
|
| Medical Records | 3 | 2010 | 190 | 0.050 |
Why?
|
| Kidney | 2 | 2010 | 1491 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2010 | 2497 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2015 | 167 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2007 | 780 | 0.050 |
Why?
|
| Acrylamides | 1 | 2024 | 74 | 0.050 |
Why?
|
| Cell Count | 2 | 1995 | 315 | 0.050 |
Why?
|
| Body Burden | 1 | 2003 | 7 | 0.050 |
Why?
|
| Maximum Allowable Concentration | 1 | 2003 | 15 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2009 | 669 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2001 | 216 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 266 | 0.050 |
Why?
|
| Pentoxifylline | 1 | 2002 | 23 | 0.050 |
Why?
|
| Abdomen | 1 | 2023 | 140 | 0.050 |
Why?
|
| G2 Phase | 1 | 2002 | 39 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2025 | 314 | 0.050 |
Why?
|
| Telomerase | 1 | 2025 | 252 | 0.050 |
Why?
|
| Forecasting | 2 | 2017 | 386 | 0.050 |
Why?
|
| Vasopressins | 2 | 1993 | 60 | 0.050 |
Why?
|
| Acid-Base Equilibrium | 1 | 2002 | 23 | 0.050 |
Why?
|
| Electrodes | 1 | 2022 | 111 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2002 | 117 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2001 | 17 | 0.040 |
Why?
|
| Comorbidity | 2 | 2017 | 1652 | 0.040 |
Why?
|
| Apoptosis | 1 | 2010 | 2436 | 0.040 |
Why?
|
| Research Design | 2 | 2018 | 1139 | 0.040 |
Why?
|
| Certification | 2 | 2015 | 117 | 0.040 |
Why?
|
| Peptides | 1 | 2007 | 991 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 1998 | 46 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 878 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1511 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 2016 | 719 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2001 | 66 | 0.040 |
Why?
|
| Rats | 3 | 2002 | 5574 | 0.040 |
Why?
|
| Probability | 1 | 2001 | 308 | 0.040 |
Why?
|
| Skull Neoplasms | 1 | 2000 | 20 | 0.040 |
Why?
|
| Mastectomy | 1 | 2022 | 188 | 0.040 |
Why?
|
| Carboplatin | 2 | 2011 | 168 | 0.040 |
Why?
|
| Alveolar Process | 1 | 2000 | 5 | 0.040 |
Why?
|
| Camptothecin | 2 | 2011 | 139 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2025 | 1236 | 0.040 |
Why?
|
| Indoles | 1 | 2024 | 509 | 0.040 |
Why?
|
| Maxilla | 1 | 2000 | 36 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2002 | 189 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2000 | 67 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 70 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2000 | 84 | 0.040 |
Why?
|
| Palate | 1 | 2000 | 40 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 1998 | 758 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 430 | 0.040 |
Why?
|
| Ontario | 1 | 1999 | 91 | 0.040 |
Why?
|
| APACHE | 1 | 1999 | 67 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2026 | 1790 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2019 | 62 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 1999 | 22 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 420 | 0.040 |
Why?
|
| Dexamethasone | 2 | 2012 | 368 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 1999 | 53 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 1370 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2001 | 250 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 181 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2019 | 319 | 0.030 |
Why?
|
| Lung Injury | 1 | 2002 | 262 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 1998 | 37 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 153 | 0.030 |
Why?
|
| Length of Stay | 2 | 2007 | 1342 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 128 | 0.030 |
Why?
|
| Cell Line | 2 | 2008 | 2809 | 0.030 |
Why?
|
| Safety | 1 | 2000 | 346 | 0.030 |
Why?
|
| Reoperation | 2 | 2012 | 633 | 0.030 |
Why?
|
| Immune System | 1 | 2019 | 181 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1998 | 302 | 0.030 |
Why?
|
| Neurosurgeons | 1 | 2017 | 17 | 0.030 |
Why?
|
| Tyrphostins | 1 | 1997 | 18 | 0.030 |
Why?
|
| Triage | 1 | 2020 | 243 | 0.030 |
Why?
|
| Headache | 1 | 1998 | 149 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2019 | 379 | 0.030 |
Why?
|
| Patient Admission | 1 | 1999 | 216 | 0.030 |
Why?
|
| Medicaid | 1 | 2021 | 472 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1998 | 250 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 566 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2000 | 560 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2021 | 945 | 0.030 |
Why?
|
| Movement | 2 | 2010 | 290 | 0.030 |
Why?
|
| Biopsy | 1 | 2000 | 1073 | 0.030 |
Why?
|
| Syndrome | 2 | 2008 | 377 | 0.030 |
Why?
|
| Caregivers | 1 | 2025 | 1079 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 1993 | 266 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 207 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 128 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 147 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 1074 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 48 | 0.030 |
Why?
|
| Contrast Media | 1 | 1998 | 492 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2016 | 134 | 0.030 |
Why?
|
| Ions | 1 | 2015 | 66 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 395 | 0.030 |
Why?
|
| Echocardiography | 1 | 2018 | 645 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 127 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 196 | 0.030 |
Why?
|
| Netherlands | 1 | 2014 | 84 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 558 | 0.030 |
Why?
|
| Myocardium | 1 | 2020 | 948 | 0.030 |
Why?
|
| Sigmoid Neoplasms | 1 | 1994 | 5 | 0.030 |
Why?
|
| Seizures | 1 | 1998 | 489 | 0.030 |
Why?
|
| North Carolina | 1 | 2014 | 127 | 0.030 |
Why?
|
| Vital Capacity | 1 | 2015 | 293 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 979 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2015 | 451 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 279 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2014 | 119 | 0.020 |
Why?
|
| Spatial Analysis | 1 | 2013 | 20 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2018 | 667 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2008 | 414 | 0.020 |
Why?
|
| Neutrophils | 1 | 2019 | 1132 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 150 | 0.020 |
Why?
|
| Erythrocyte Deformability | 1 | 1993 | 23 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2006 | 2962 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2014 | 179 | 0.020 |
Why?
|
| Animals | 6 | 2010 | 38030 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1323 | 0.020 |
Why?
|
| Rheology | 1 | 1993 | 94 | 0.020 |
Why?
|
| Critical Illness | 1 | 1999 | 905 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1995 | 595 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 994 | 0.020 |
Why?
|
| Fiducial Markers | 1 | 2012 | 9 | 0.020 |
Why?
|
| Hospital Information Systems | 1 | 1992 | 15 | 0.020 |
Why?
|
| Neurophysins | 1 | 1992 | 5 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1992 | 61 | 0.020 |
Why?
|
| Medical Errors | 1 | 2013 | 124 | 0.020 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1992 | 18 | 0.020 |
Why?
|
| Arginine Vasopressin | 1 | 1992 | 44 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 175 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1993 | 533 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 160 | 0.020 |
Why?
|
| Lactic Acid | 1 | 1993 | 295 | 0.020 |
Why?
|
| Protein Precursors | 1 | 1992 | 127 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1500 | 0.020 |
Why?
|
| Etoposide | 1 | 2011 | 169 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2002 | 4112 | 0.020 |
Why?
|
| Africa | 1 | 1991 | 119 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 851 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 568 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 9 | 0.020 |
Why?
|
| Patient Participation | 1 | 2014 | 454 | 0.020 |
Why?
|
| Child | 3 | 2025 | 22638 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2010 | 24 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 79 | 0.020 |
Why?
|
| Carmustine | 1 | 2010 | 52 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 48 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 120 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 3005 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3633 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 258 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 81 | 0.020 |
Why?
|
| Vincristine | 1 | 2010 | 148 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 294 | 0.020 |
Why?
|
| United Kingdom | 1 | 1991 | 376 | 0.020 |
Why?
|
| Physical Phenomena | 2 | 1999 | 13 | 0.020 |
Why?
|
| Kinetics | 1 | 1993 | 1553 | 0.020 |
Why?
|
| Urination Disorders | 1 | 2009 | 15 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 2009 | 11 | 0.020 |
Why?
|
| Cystitis | 1 | 2009 | 24 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 237 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 2112 | 0.020 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2008 | 12 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 137 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2010 | 169 | 0.020 |
Why?
|
| Ipilimumab | 1 | 2009 | 44 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 470 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 473 | 0.020 |
Why?
|
| Smoking | 1 | 2015 | 1478 | 0.020 |
Why?
|
| Capecitabine | 1 | 2008 | 56 | 0.020 |
Why?
|
| Premedication | 1 | 2008 | 45 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 1136 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 386 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 845 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 867 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2007 | 34 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1176 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 108 | 0.020 |
Why?
|
| Palliative Care | 2 | 2012 | 1032 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 275 | 0.020 |
Why?
|
| Forearm | 1 | 2008 | 141 | 0.020 |
Why?
|
| Quebec | 1 | 2007 | 10 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1992 | 1114 | 0.020 |
Why?
|
| Prednisone | 1 | 2008 | 229 | 0.020 |
Why?
|
| Diarrhea | 1 | 2008 | 190 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 74 | 0.020 |
Why?
|
| Medical Audit | 1 | 2007 | 77 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2007 | 116 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2006 | 30 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 567 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 536 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 6449 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 530 | 0.010 |
Why?
|
| Pedigree | 1 | 2007 | 507 | 0.010 |
Why?
|
| HIV Infections | 1 | 2001 | 3210 | 0.010 |
Why?
|
| Epitopes | 1 | 2008 | 479 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1992 | 878 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2010 | 585 | 0.010 |
Why?
|
| Antiemetics | 1 | 2005 | 51 | 0.010 |
Why?
|
| Cognition | 1 | 2013 | 1286 | 0.010 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2004 | 40 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 2088 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 2835 | 0.010 |
Why?
|
| Esthetics | 1 | 2003 | 49 | 0.010 |
Why?
|
| Testosterone | 1 | 2007 | 419 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 61 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2003 | 107 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2002 | 16 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2005 | 378 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 2003 | 59 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 91 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1993 | 4565 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2007 | 1037 | 0.010 |
Why?
|
| Cricetulus | 1 | 2002 | 115 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 295 | 0.010 |
Why?
|
| Spheroids, Cellular | 1 | 2002 | 81 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2010 | 5234 | 0.010 |
Why?
|
| Craniotomy | 1 | 2000 | 83 | 0.010 |
Why?
|
| Iridium Radioisotopes | 1 | 1999 | 4 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2000 | 303 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 1 | 1999 | 7 | 0.010 |
Why?
|
| Skull | 1 | 2000 | 162 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 33 | 0.010 |
Why?
|
| Antisickling Agents | 1 | 1999 | 8 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2000 | 140 | 0.010 |
Why?
|
| Oxyhemoglobins | 1 | 1999 | 28 | 0.010 |
Why?
|
| Allosteric Regulation | 1 | 1999 | 100 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 503 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1999 | 252 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 1160 | 0.010 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1997 | 20 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1997 | 38 | 0.010 |
Why?
|
| Phospholipase C gamma | 1 | 1997 | 28 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1997 | 69 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1997 | 84 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1997 | 294 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1999 | 431 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1999 | 384 | 0.010 |
Why?
|
| Nitriles | 1 | 1997 | 211 | 0.010 |
Why?
|
| Bronchial Neoplasms | 1 | 1995 | 15 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 820 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 1995 | 205 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1994 | 344 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 11888 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1992 | 238 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1992 | 68 | 0.010 |
Why?
|
| Microcirculation | 1 | 1992 | 142 | 0.010 |
Why?
|
| Orthopedics | 1 | 1992 | 181 | 0.000 |
Why?
|
| Mice | 1 | 1999 | 18266 | 0.000 |
Why?
|